Fingolimod

Sarcoma

Institut du Cancer de Montpellier - Val d'AurelleSmall moleculeN/AActive

D

30/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 73/ 100

Competitive context

91 Active assets in the Sarcoma cohort.

Asset / Sponsor	Phase	Rating
ETOPOSIDE National Cancer Institute (NCI)	Phase 2	BB
Ifosfamide City of Hope Medical Center	Phase 3	BB
Cyclophosphamide Essen Biotech	Phase 2	BB
Carboplatin OHSU Knight Cancer Institute	Phase 2	BB
Inno-206 City of Hope Medical Center	Phase 3	BB

View all 50 →

Same molecule, other indications

Fingolimod is also rated in:

relapsing-remitting multiple sclerosisDormant

A

Indicative ·

82 / 100

multiple sclerosisDormant

BB

Indicative ·

70 / 100

cerebral degenerationDormant

BB

Indicative ·

65 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.